MicroDose collaborates with Novartis on dry powder inhaler
MicroDose Technologies of New Jersey, US has entered into a multi-product development and licensing agreement with Novartis for the MicroDose proprietary dry powder inhaler (DPI). The deal follows the successful completion of an exploratory study performed with the DPI.
MicroDose Technologies of New Jersey, US has entered into a multi-product development and licensing agreement with Novartis for the MicroDose proprietary dry powder inhaler (DPI). The deal follows the successful completion of an exploratory study performed with the DPI.
MicroDose could receive up to US$125m in milestones for the successful development of the first five products. In addition, Novartis will pay MicroDose development costs and royalties on product sales, and will fund the necessary development, manufacturing and marketing costs for all products. In return, Novartis will receive exclusive rights to the MicroDose inhaler technology for its proprietary respiratory products.
MicroDose is a privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries. The MicroDose DPI is a handheld, low cost, breath activated device that uses piezo electronics to efficiently deliver a broad range of compounds independent of inhalation effort.
The company is developing an inhaled insulin product through its joint venture, QDose, and is also co-developing, with the University of Pittsburgh, an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense. It also has internal development programmes underway for combination oral dosage products in the areas of diabetes, hypertension and hyperlipidemia.